8-K: Quince Therapeutics Completes Enrollment in Pivotal Phase 3 Trial for Ataxia-Telangiectasia Treatment

Quince Therapeutics, Inc. announced the completion of patient enrollment in its pivotal Phase 3 NEAT clinical trial for eDSP, a potential first-to-market treatment for the rare neurodegenerative disease Ataxia-Telangiectasia.

Summary

• Completed patient enrollment in the pivotal Phase 3 NEAT clinical trial for eDSP, its lead asset for treating Ataxia-Telangiectasia (A-T).
• A total of 105 participants were enrolled, comprising 83 participants in the six to nine-year-old primary analysis population and 22 participants aged 10 years or older.
• The study is powered at approximately 90% to determine statistical significance for the primary endpoint in the six to nine-year-old primary analysis population.
• All enrolled participants to date have elected to transition to the NEAT open label extension (OLE) study.
• Topline results from the Phase 3 NEAT clinical trial are expected in the first quarter of 2026.
• Assuming positive study results, a New Drug Application (NDA) submission to the U.S. FDA is planned for the second half of 2026.
• The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA, and eDSP has FDA Fast Track designation for A-T.

Sentiment

Score: 8

Explanation: The completion of enrollment in a pivotal Phase 3 trial is a major de-risking event for a biotechnology company, especially for a rare disease with no approved treatments. This milestone keeps the company on track for significant future catalysts (topline results, NDA submission) and indicates strong operational execution. The high powering and participant retention in the OLE are also positive indicators.

Positives

• Completion of enrollment in a pivotal Phase 3 clinical trial is a significant de-risking milestone for a biotechnology company.
• The trial is well-designed with approximately 90% powering for statistical significance in the primary analysis population.
• All participants to date have elected to transition to the open-label extension study, indicating potential positive early experiences or commitment.
• eDSP has FDA Fast Track designation, potentially accelerating the review process.
• The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA, providing clarity on the regulatory pathway.
• Ataxia-Telangiectasia currently has no approved therapeutic treatments in any global market, positioning eDSP as a potential first-to-market therapy.

Risks

• Inherent uncertainties, risks, and assumptions could cause actual results to differ materially from expectations.
• Future events may not prove to be accurate as assumed in forward-looking statements.
• Factors that could cause actual results to differ include those described in the "Risk Factors" section of the company's Quarterly Report on Form 10-Q filed on May 13, 2025, and other SEC reports.

Future Outlook

Quince Therapeutics expects to report topline results from its Phase 3 NEAT clinical trial in the first quarter of 2026. Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026, aiming to advance a first-to-market treatment for Ataxia-Telangiectasia.

Management Comments

• "The completion of enrollment in our pivotal Phase 3 NEAT clinical trial evaluating eDSP for the treatment of A-T is a major milestone for Quince that places us one step closer to advancing a first-to-market treatment for this devasting disease."
• "We are confident that we have executed a well-designed study with a high degree of scientific integrity and vigilant operational oversight."

Industry Context

Ataxia-Telangiectasia (A-T) is a severe, inherited neurodegenerative and immunodeficiency disorder with a median lifespan of approximately 25 to 30 years. There are currently no approved therapeutic treatments for A-T in any global market, representing a significant unmet medical need. Quince's eDSP, leveraging its proprietary AIDE technology, aims to address this by providing the efficacy of corticosteroids while mitigating their typical dose-limiting toxicities, potentially offering the first approved treatment for this devastating rare disease.

Comparison to Industry Standards

• There are currently no approved therapeutic treatments for Ataxia-Telangiectasia in any global market, making direct comparisons to existing therapies or industry benchmarks for A-T treatment impossible.
• The trial's design, including a Special Protocol Assessment (SPA) agreement with the FDA and Fast Track designation, aligns with best practices for accelerating development of therapies for high unmet medical needs in rare diseases, similar to other companies developing orphan drugs.
• The 90% powering for statistical significance in the primary analysis population is a robust design, comparable to well-designed pivotal trials in the pharmaceutical industry.

Stakeholder Impact

• Shareholders: Positive impact due to significant de-risking of the lead asset, potential for future value creation upon positive trial results and regulatory approval, and progression towards a potential first-to-market therapy.
• Patients (Ataxia-Telangiectasia): Potential for a first-ever approved therapeutic treatment for a devastating neurodegenerative disease, offering hope for improved quality of life and potentially extended lifespan.
• Employees: Positive impact from achieving a major company milestone, validating research and development efforts.
• Regulatory Authorities (FDA): Continued engagement through SPA agreement and Fast Track designation, indicating progress in addressing an unmet medical need.

Next Steps

• Report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026.
• Submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026, assuming positive study results.

Key Dates

Recommendation

Keywords

Quince Therapeutics, QNCX, Ataxia-Telangiectasia, A-T, eDSP, Phase 3 clinical trial, NEAT trial, rare disease, neurodegenerative disease, biotechnology, clinical development, FDA Fast Track, Special Protocol Assessment, NDA submission, patient enrollment